Spravato (Esketamine) for Treatment Resistant Depression – An FDA Approved “Breakthrough Therapy”

Last Updated on September 16, 2020 by In March 2019, the U.S. Food and Drug Administration (FDA) announced the approval of Spravato (Esketamine) for use in patients diagnosed with treatment-resistant depression. Spravato is a nasal spray that can only be administered by an approved health care provider, in the physician’s office or clinic, because the […]




Read More...